CMS said in its latest Medicare Drug Price Negotiation Program guidance it still working on a process to allow manufacturers to avoid providing a 340B price and a negotiated fair price for the same drug.

340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance

The latest guidance to implement first-time drug price negotiation under Medicare said federal officials still are looking for a process [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at